ARTICLE | Clinical News

PSI-7977: Phase IIb started

August 30, 2010 7:00 AM UTC

Pharmasset began a placebo-controlled, U.S. Phase IIb trial to evaluate 200 or 400 mg oral PSI-7977 once daily in combination with standard of care (SOC) of pegylated interferon alfa 2a and ribavirin for 12 weeks followed by SOC alone for 12 or 36 weeks in 125 treatment-naïve patients with HCV genotype 1. According to a response-guided therapy design, patients who have an extended rapid virologic response (eRVR) at 4 weeks through 12 weeks will receive 12 weeks of SOC alone, while those not achieving an eRVR will receive SOC alone for 36 weeks. ...